Alcami Announces Grand Opening of St. Louis, Missouri Facility in Cortex Innovation Community

This content was submitted directly to this website by the supplier.

Alcami Corporation, a leading provider of custom development and manufacturing services for the pharmaceutical and biotechnology industries, today announced the unveiling of its new analytical testing facility, located at 4260 Forest Park Avenue, in the Cortex Innovation Community, a 200-acre innovation hub and technology district located in St. Louis's historic Central West End neighborhood. Alcami will welcome the public with a grand opening ceremony September 13, 2017, sharing the company's outlook and key capabilities with clients and community leaders. The state-of-the-art facility will be Alcami's new Center of Excellence for its advanced analytical testing operations.

Alcami's centrally located new St. Louis campus is easily accessible for both domestic and international business partners. The site offers a variety of essential technologies for development and testing. It boasts a significant laboratory expansion as well as a range of new capabilities, including a low humidity room used to test and handle hygroscopic materials; isolator technology that will serve as an upgrade from traditional sterility capabilities; Inductively Coupled Plasma Mass Spectrometry (ICP-MS) equipment designed to assist clients in their transitions from USP wet chemistry heavy metal requirements; a photosensitive materials handling lab to protect light-sensitive materials and more.

"We are delighted to expand our laboratory capabilities in St. Louis and are proud to call the Cortex Innovation Community our new home," said Dr. Stephan Kutzer, CEO, President and Chairman of Alcami Corporation. "The successful completion of this investment is an integral moment in Alcami's history and will solidify our position as a leading analytical testing solution provider for the pharma and biotech industry."

The site specializes in chemical and microbiological analysis, including raw material and antibiotic testing, drug product release and stability, and full drug product manufacturing evaluation, including water analysis, environmental monitoring, and in-process evaluations for both sterile and non-sterile drug product including controlled substances.

"With the investment in advanced equipment and increased lab support, we have strengthened our ability to serve clients and are on course to lead the market in customized services," said Ted Dolan, Alcami's Chief Operating Officer. "We look forward to expanding our client-centric innovations to the pharmaceutical and biotechnology industries."

More in Home